Intellia Therapeutics (NTLA) incurred a fourth-quarter 2024 loss of 1.24pershare(excludingone−timeexpensesofchangeinfairvalueofinvestments),whichwasnarrowerthantheZacksConsensusEstimateofalossof1.32. In the year-ago quarter, Intellia had incurred a loss of 1.46pershare.Includingone−timeexpenses,thecompanyreportedalossof1.27 per share in the fourth quarter of 2024.See the Zacks Earnings Calendar to stay ahead of market-making news.The company’s total revenues currentl ...